{{Rsnum
|rsid=7120118
|Gene=NR1H3
|Chromosome=11
|position=47264739
|Orientation=plus
|GMAF=0.4637
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=NR1H3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.7 | 40.7 | 49.6
| HCB | 53.7 | 37.5 | 8.8
| JPT | 54.9 | 37.2 | 8.0
| YRI | 28.6 | 47.6 | 23.8
| ASW | 15.8 | 47.4 | 36.8
| CHB | 53.7 | 37.5 | 8.8
| CHD | 61.1 | 30.6 | 8.3
| GIH | 18.8 | 49.5 | 31.7
| LWK | 19.1 | 40.0 | 40.9
| MEX | 13.8 | 41.4 | 44.8
| MKK | 16.7 | 45.5 | 37.8
| TSI | 4.0 | 34.7 | 61.4
| HapMapRevision=28
}}
{{PMID Auto GWAS
|PMID=19060910
|Trait=HDL cholesterol
|Title=Genome-wide association analysis of metabolic traits in a birth cohort from a founder population
|RiskAllele=G
|Pval=4E-8
|OR=0.04
|ORtxt=[0.03-0.05] mmol/l increase
|OA=1
}}

{{PharmGKB
|RSID=rs7120118
|Name_s=
|Gene_s=NR1H3, MADD
|Feature=
|Evidence=PubMed ID:19060910; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. (Initial Sample Size: 4,763 individuals; Replication Sample Size: NR); (Region: 11p11.2; Reported Gene(s): NR1H3; Risk Allele: rs7120118-G); (p-value= 0.00000004).This variant is associated with HDL cholesterol.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740271
}}

The C allele of this SNP in the [[NR1H3]] gene is associated with increased (but still low) risk of [[progressive supranuclear palsy]]. {{PMID|17357082|OA=1
}}

{{PMID Auto
|PMID=22029530
|Title=A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia
|OA=1
}}

{{PMID Auto
|PMID=22027013
|Title=Genetic analysis of genes involved in amyloid-β degradation and clearance in Alzheimer's disease
}}

{{PMID Auto
|PMID=19299407
|Title=Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample.
|OA=1
}}

{{PMID Auto
|PMID=21562465
|Title=Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7120118
|overall_frequency_n=46
|overall_frequency_d=128
|overall_frequency=0.359375
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=41
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23838803
|Title=Association of liver X receptors (LXRs) genetic variants to gallbladder cancer susceptibility
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}